HC Wainwright Has Bearish Estimate for CTMX Q1 Earnings

CytomX Therapeutics, Inc. (NASDAQ:CTMX) – HC Wainwright cut their Q1 2026 earnings per share estimates for shares of CytomX Therapeutics in a report issued on Monday, March 16th. HC Wainwright analyst M. Kapoor now anticipates that the biotechnology company will earn ($0.14) per share for the quarter, down from their prior forecast of ($0.08). HC Wainwright has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for CytomX Therapeutics’ current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for CytomX Therapeutics’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.56) EPS and FY2027 earnings at ($0.65) EPS.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14). CytomX Therapeutics had a negative return on equity of 20.65% and a negative net margin of 22.79%.The company had revenue of $0.66 million during the quarter, compared to the consensus estimate of $7.33 million.

CTMX has been the topic of a number of other reports. JPMorgan Chase & Co. raised CytomX Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $7.00 to $12.00 in a research note on Monday. Cantor Fitzgerald increased their target price on CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a report on Wednesday, February 4th. Wedbush raised their price target on CytomX Therapeutics from $6.00 to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday. Barclays lifted their price target on CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 4th. Finally, Guggenheim reissued a “buy” rating and set a $10.00 price objective on shares of CytomX Therapeutics in a research note on Monday, March 9th. Eight research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.50.

CytomX Therapeutics Stock Down 19.3%

Shares of NASDAQ:CTMX opened at $5.45 on Wednesday. The stock has a market cap of $923.39 million, a PE ratio of -136.25 and a beta of 2.44. The company’s fifty day moving average is $5.26 and its 200 day moving average is $4.09. CytomX Therapeutics has a 52 week low of $0.40 and a 52 week high of $8.21.

Institutional Trading of CytomX Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Orbimed Advisors LLC purchased a new position in shares of CytomX Therapeutics during the 2nd quarter worth $19,208,000. Commodore Capital LP bought a new position in CytomX Therapeutics in the 2nd quarter worth $17,462,000. Perceptive Advisors LLC purchased a new position in CytomX Therapeutics during the second quarter valued at $15,876,000. Franklin Resources Inc. bought a new stake in CytomX Therapeutics during the second quarter valued at about $13,096,000. Finally, Vivo Capital LLC bought a new stake in CytomX Therapeutics during the second quarter valued at about $13,096,000. 67.77% of the stock is owned by hedge funds and other institutional investors.

CytomX Therapeutics News Summary

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Phase I Varseta‑M data show stronger-than-expected responses (e.g., ~32% response at the higher dose and ~7.1 months estimated PFS), which sparked a major rally and underpins the stock’s recent upside. Zacks: CTMX Stock Rallies
• Positive Sentiment: Multiple broker actions followed the clinical readout — JPMorgan upgraded CTMX to overweight (new $12 PT) and other firms (Wedbush, HC Wainwright) raised price targets (HC Wainwright to $17) or issued Buy/outperform opinions, adding momentum. Seeking Alpha: Upgrade Coverage
• Neutral Sentiment: Company posted Q4 results and released the earnings slide deck/transcript; these materials reiterate clinical progress but showed weak near-term revenue — useful for modeling but not a catalyst by themselves. Q4 Slide Deck
• Negative Sentiment: CytomX priced a $250M underwritten public offering (45.99M shares at $5.30 and pre‑funded warrants), which is dilutive and typically puts near‑term pressure on the share price. Closing expected March 19, subject to conditions. GlobeNewswire: Offering Priced
• Negative Sentiment: Q4 results missed expectations: EPS ($0.22) vs. consensus ($0.08) loss and revenue of $0.66M well below estimates, highlighting current financial drag. Zacks: Q4 Miss
• Negative Sentiment: HC Wainwright trimmed near‑term and FY2026 EPS forecasts (Q1–Q4 and FY26/FY27 EPS lowered), signaling expectations for higher cash burn or slower commercial/partner revenue in the near term despite keeping a Buy rating. MarketBeat: Analyst Estimate Changes

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.